Potent antibodies neutralize HIV and could offer new therapy, study finds
Mice with HIV that were given a combination of five potent antibodies were able to effectively suppress the virus for a 60-day period, longer than current antiretroviral drugs which require daily application. The antibodies target HIV-1’s surface protein gp160, which is notorious for evading the immune system’s attacks by constantly mutating.
(Medical Xpress)—Having HIV/AIDS is no longer a death sentence, but it's still a lifelong illness that requires an expensive daily cocktail of drugs—and it means tolerating those drugs' side effects and running the risk of resistance. Researchers at The Rockefeller University may have found something better: they've shown that a therapeutic approach harnessing proteins from the human immune system can suppress the virus in mice without the need for daily application and could one day be used in humans to treat the disease.
Florian Klein and colleagues in Michel Nussenzweig's Laboratory of Molecular Immunology found that a combination of five different antibodies—proteins the immune system uses to fight infection—effectively suppressed HIV-1 replication and kept the virus at bay for a 60 day period after termination of therapy thanks to their longer half-life, while current antiretroviral drugs require daily intake.
These especially potent antibodies were only recently discovered, some of them by several of Klein's colleagues in the Nussenzweig laboratory. Called broadly-neutralizing antibodies, they were identified and cloned from HIV-infected patients whose immune systems showed an unusually high ability to neutralize HIV. In recent years the potent antibodies were found to prevent HIV from infecting non-human primates, demonstrating the possibility for a vaccine in humans. But they were thought to have little or no effect on established infections.
"Antibodies had been written off as a treatment for HIV/AIDS because previous studies showed only a limited effect on controlling the virus," says Klein. "But that was before these more potent antibodies were discovered. We wanted to readdress this question using these new tools."
HIV-1 is notorious for evading the immune system's attacks by constantly mutating, but the new antibodies are able to throw a wrench in that strategy. The key is in the combination. The antibodies target HIV-1's surface protein gp160, a large molecule that forms a spike that seeks out host cells and attaches to them. One antibody alone wasn't enough to quell the virus; neither was a mix of three. But five of them in unison proved too complicated for gp160 to mutate its way out of.
The researchers used "humanized" mice for the study, provided by Alexander Ploss in the Laboratory of Virology and Infectious Disease, because normal mice don't have the right receptors to be infected with HIV-1.
"Although HIV-1 infection in humanized mice differs in many important aspects from infection in humans, the results are encouraging to investigate these antibodies in clinical trials," says Klein. "It also may be that a combination of antibodies and the already established antiretroviral therapy is more efficacious than either alone," says Klein.
"If this could be used as a treatment one day, it is conceivable that patients would only need to take traditional drugs until the virus is controlled, and then receive antibodies every two to three months to maintain that control. We're eager to explore if a benefit in HIV-1-treatment can be achieved in humans."
More information: Klein, F. et al., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature online, October 24, 2012. www.nature.com/nat… re11604.html
Journal reference: Nature
Provided by Rockefeller University
- Researchers discuss challenges to developing broadly protective HIV vaccines Sep 07, 2011 | not rated yet | 0
- Scientists identify broad and potent HIV antibodies that mimic CD4 binding Jul 20, 2011 | not rated yet | 0
- Exhausted B cells fail to fight HIV Jul 14, 2008 | not rated yet | 0
- New strategy proposed for designing antibody-based HIV vaccine Jun 14, 2009 | not rated yet | 0
- Neutralizing HIV Jul 18, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Assumptions of Griffith's fracture theory
10 hours ago Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
Current leading voltage or vice versa concept
11 hours ago Hello, I was wondering if there is a conceptual explanation for when current leads voltage or vice versa for capacitors or inductors with AC...
Angular Frequency of AC voltage
14 hours ago Hello, I am wondering, what is the physical interpretation of the angular frequency of AC voltage? I don't see the physicality of what the angle...
Modeling Rigid Body - Unsure about Euler angles and angular velocity
15 hours ago I'm modeling a single 3D rigid body in preparation for some more complicated modeling in order to gain a better understanding of Euler angles, the...
Function for a bullet's path
16 hours ago I've been mulling this over all weekend, and I've decided to get some help on this. The problem is writing a function to describe a bullet's path....
Elementary questions relating to Newton's laws of motion
17 hours ago i) If a wall breaks when it gets hit by a cannonball, did the wall exert an equal and opposite force on the cannonball? ii) Would the force...
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Immunology 18 hours ago | 4.7 / 5 (17) | 7 |
(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...
Immunology May 20, 2013 | 5 / 5 (1) | 0 |
Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.
Immunology May 20, 2013 | 5 / 5 (5) | 0 |
Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...
Immunology May 16, 2013 | 4.8 / 5 (5) | 0 |
Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...
Immunology May 16, 2013 | not rated yet | 0
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
1 hour ago | 4.5 / 5 (2) | 0 |
The level of immunity to the recently circulating H7N9 influenza virus in an urban and rural population in Vietnam is very low, according to the first population level study to examine human immunity to the virus, which was ...
41 minutes ago | not rated yet | 0 |
Researchers at Emory University have identified a protein that stimulates a pair of "orphan receptors" found in the brain, solving a long-standing biological puzzle and possibly leading to future treatments for neurological ...
38 minutes ago | not rated yet | 0 |
Widely available in pharmacies and health stores, phosphatidylserine is a natural food supplement produced from beef, oysters, and soy. Proven to improve cognition and slow memory loss, it's a popular treatment for older ...
8 minutes ago | not rated yet | 0 |
In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis (TB) bacteria in laboratory culture. The finding ...
53 minutes ago | 5 / 5 (1) | 0 |
Prostaglandin analogues (PGAs), drugs which lower intraocular pressure, are often the first line of treatment for people with glaucoma, but their use is not without risks. PGAs have long been associated with blurred vision, ...
40 minutes ago | not rated yet | 0